Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New flu vaccine shows promise for teens and adults

NCT ID NCT05513053

Vaccine Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a recombinant flu vaccine (RIV4) in over 1,300 people aged 9 to 49. The goal was to see if the immune response in children and teens (9-17) was as good as in adults (18-49). Researchers measured antibody levels before and 29 days after vaccination. The trial also monitored safety for all participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Quadrivalent recombinant influenza vaccine (RIV4), also known as Supemtek or Flublok Quadrivalent
What this could lead to
If successful, this could confirm that the recombinant flu vaccine works as well in teens as in adults, offering a safe option for younger age groups.
What could go wrong
This is a completed phase 3 trial, but results only show immune response and short-term safety. Long-term protection and real-world effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,308 people

The number who actually took part.

Started

Oct 2022

Finished

Oct 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 to 49 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 9 to 49 years on the day of inclusion * A female participant was eligible to participate if she was not pregnant or breastfeeding and one of the following conditions applies: 1) was of non-childbearing potential. To be considered of non-childbearing potential, a female should have been pre-menarche, post-menopausal for at least 1 year, or surgically sterile OR 2) was of childbearing potential and agreed to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first study intervention administration until at least 4 weeks after the last study intervention administration * Assent form or informed consent form had been signed and dated by the participant (based on local regulations), and if applicable informed consent form had been signed and dated by the parent(s) or another legally acceptable representative Exclusion Criteria: * Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) * Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances * Thrombocytopenia * Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on the Investigator's judgment * Personal or family history of Guillain-Barre Syndrome (GBS) * Personal history of clinically significant development delay (at the discretion of the Investigator), neurologic disorder, or seizure disorder NOTE: The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza immunization are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza immunization

Contacts and locations

Locations

  • AMR - Newton Site Number : 8400021

    Newton, Kansas, 67114, United States

  • Alabama Clinical Therapeutics North Tower Site Number : 8400024

    Birmingham, Alabama, 35205, United States

  • Benchmark Research - Austin Site Number : 8400004

    Austin, Texas, 78705, United States

  • Birmingham Pediatric Associates Site Number : 8400023

    Birmingham, Alabama, 35205, United States

  • California Research Foundation Site Number : 8400003

    San Diego, California, 92123-1881, United States

  • Coastal Carolina Research Center - N Charleston Site Number : 8400022

    North Charleston, South Carolina, 29405, United States

  • Coastal Pediatric Research Charleston Site Number : 8400005

    Charleston, South Carolina, 29414, United States

  • Investigational Site Number : 2030001

    Jindřichův Hradec, 37701, Czechia

  • Investigational Site Number : 6160003

    Bydgoszcz, 85-796, Poland

  • Investigational Site Number : 6160004

    PuÅ'awy, Lubusz Voivodeship, 24-100, Poland

  • Investigational Site Number : 6160005

    Siemianowice Śląskie, Silesian Voivodeship, 41-103, Poland

  • Investigational Site Number : 6160006

    Tarnów, 33-100, Poland

  • Investigational Site Number : 6160007

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-079, Poland

  • Investigational Site Number : 6160008

    Warsaw, 02-637, Poland

  • Investigational Site Number : 6160010

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-048, Poland

  • Investigational Site Number : 6160012

    Wroclaw, 53-149, Poland

  • Investigational Site Number : 7240001

    Móstoles, 28938, Spain

  • Investigational Site Number : 7240005

    Málaga, 29015, Spain

  • Investigational Site Number : 7240006

    Centelles, Barcelona [Barcelona], 08540, Spain

  • Investigational Site Number : 7240007

    Seville, 41014, Spain

  • Investigational Site Number : 7240018

    Madrid, 28660, Spain

  • J. Lewis Research Site Number : 8400017

    Salt Lake City, Utah, 84109, United States

  • JBR Clinical Research Site Number : 8400001

    Salt Lake City, Utah, 84107, United States

  • Kentucky Pediatics / Adult Research Site Number : 8400010

    Bardstown, Kentucky, 40004, United States

  • Meridian Clinical Research Norfolk Site Number : 8400011

    Norfolk, Nebraska, 68701, United States

  • Meridian Clinical Research Site Number : 8400006

    Binghamton, New York, 13905, United States

  • Meridian Clinical Research- Sioux City Site Number : 8400007

    Sioux City, Iowa, 51106, United States

  • Ohio Pediatric Research Site Number : 8400020

    Dayton, Ohio, 45414, United States

  • Rainbow Pediatrics Site Number : 8400014

    Barnwell, South Carolina, 29812, United States

  • The Children's Clinic Of Jonesboro PA Site Number : 8400025

    Jonesboro, Arkansas, 72401, United States

  • Velocity Clinical Research Lincoln Site Number : 8400013

    Lincoln, Nebraska, 68510, United States

  • Velocity Clinical Research Portsmouth Site Number : 8400015

    Portsmouth, Virginia, 23703, United States

  • Velocity Clinical Research Site Number : 8400012

    New Orleans, Louisiana, 70119, United States

  • Velocity Clinical Research Vestal Site Number : 8400016

    Vestal, New York, 13850, United States

  • Velocity Clinical Research, Omaha Site Number : 8400009

    Omaha, Nebraska, 68134, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.